Home > Healthcare > Medical Devices > Medical Supplies > Biosensors Market

Biosensors Market – By Type, By Technology, By Application, By End Use, & Global Forecast, 2024 – 2032

  • Report ID: GMI747
  • Published Date: Oct 2024
  • Report Format: PDF

Biosensors Market Size

The global biosensors market size was valued at around USD 30.1 billion in 2023 and is estimated to grow at 7.7% CAGR from 2024 to 2032. The growing prevalence of diabetes worldwide is the primary factor driving the expansion of the business.
 

Biosensors Market

Effective management and control of diabetes are essential to avoid complications such as kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. According to data provided by the World Health Organization (WHO), the prevalence of diabetes has been rising rapidly in low- and middle-income countries compared to high-income countries as of 2021. Rapid urbanization has led to sedentary lifestyles, unhealthy diets, and higher stress levels among youth, which are contributing factors for diabetes and, consequently.
 

Biosensors are analytical devices within medical and diagnostic systems that convert biological signals into measurable outputs. They consist of a biological recognition element, such as enzymes or antibodies, which interacts with a specific analyte, and a transducer that translates this interaction into a quantifiable signal. This technology facilitates rapid, sensitive, and precise detection of various health-related biomarkers, supporting early disease diagnosis and effective monitoring.
 

Biosensors Market Trends

  • Technological advancements in developing novel and next-generation biosensors are driving market progression. The growing demand for point-of-care testing is accelerating the development of miniaturized immunosensors based on the integration of electrochemical and microfluidic technologies.
     
  • Advanced biosensors have broad applications in drug discovery, diagnostics, biomedicine, environmental monitoring, food safety, and processing. Additionally, market players are increasingly investing in R&D for wearable medical devices that address fertility issues in women.
     
  • For example, Ava Science Inc. developed the Ava Fertility Tracker, a bracelet that uses biosensors to detect the fertility window, sleep quality, and stress levels in women.
     
  • Numerous startup companies are focusing on developing advanced wearable products for diagnosing and real-time monitoring of chronic conditions.
     
  • Technological advancements allow for the development of easier, portable, and more convenient testing devices, which are increasing adoption rates among insulin-dependent diabetes patients. For instance, the DEXCOM G4 Platinum features an in-built hypoglycemia safety alert, customizable alerts to monitor blood sugar drops, and a water-resistant sensor with an attached transmitter.
     

Biosensors Market Analysis

 Biosensors Market, By Type, 2021 – 2032 (USD Billion)

Based on type, the market is segmented into wearable biosensors and non-wearable biosensors. The non-wearable biosensors segment in market held a substantial 64.2% market share in 2023.
 

  • Non-wearable biosensors, such as those integrated into diagnostic devices used in point-of-care testing, offer significant advantages, including ease of use, high accuracy, and the ability to deliver rapid diagnostic results without requiring continuous user interaction.
     
  • In point-of-care settings, these biosensors are invaluable as they enable immediate testing and diagnosis, facilitating prompt treatment decisions and improving patient outcomes. Furthermore, ongoing advancements in sensor technology, such as enhanced sensitivity, miniaturization, and integration with digital platforms, further bolster their appeal and functionality.
     
Biosensors Market, By Technology (2023)

Based on technology, the biosensors market is segmented into electrochemical, optical, thermal, piezoelectric, and other technologies. The electrochemical segment dominated the market by accounting for USD 12.5 billion revenue in 2023.
 

  • This development is primarily driven by the high sensitivity, specificity, and rapid response times of electrochemical biosensors, making them ideal for a wide range of applications in the medical field.
     
  • These biosensors are essential in developing and operating various medical devices, such as glucose meters, which are extensively used for monitoring blood sugar levels in diabetic patients.
     

Based on application, the market is segmented into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and other applications. The blood glucose testing segment held a market share of 42% in 2023.
 

  • The increasing global prevalence of diabetes, driven by rising obesity, sedentary lifestyles, and aging populations, is spurring demand for convenient blood glucose monitoring solutions.
     
  • Wearable glucose monitoring devices are transforming diabetes management by providing continuous monitoring and instant data access.
     
  • Smartphone-connected glucose meters with advanced features enable users to monitor and manage glucose levels through mobile apps. These devices offer personalized insights and facilitate data sharing with healthcare providers, further fueling market expansion.
     

Based on end use, the biosensors market is segmented into point of care testing, home healthcare diagnostics, research laboratories, and other end users. The point of care testing (POC) segment is projected to reach USD 29.8 billion by 2032.
 

  • Biosensors, integral to POC testing, yield results within minutes, expediting diagnoses and decision-making. This swift response is crucial for addressing acute conditions and emergencies, where timely results lead to quick treatment, reducing waiting times and enabling immediate clinical decisions. Such efficiency is particularly valuable in emergency care and managing chronic ailments.
     
  • Additionally, POC testing’s decentralization from centralized labs not only accelerates processes but also safeguards against sample degradation. This streamlined approach not only enhances medical workflow but also reduces diagnostic costs by decreasing reliance on extensive lab setups and multiple patient visits.
     
U.S. Biosensors Market, 2021 – 2032 (USD Billion)

The U.S. dominated the North American market with the largest revenue of USD 9.5 billion in 2023 and is projected to witness substantial growth over the forecast period.
 

  • The U.S. has one of the highest healthcare expenditures globally, which contributes to investments in advanced biosensor technologies.
     
  • Additionally, insurance coverage for biosensors in the U.S. is relatively favorable compared to some other countries, making these devices more accessible and affordable for patients.
     

The biosensors market in the UK is expected to experience significant and promising expansion from 2024 to 2032.
 

  • The UK has a well-established healthcare system with advanced medical facilities, research institutions, and hospitals. This infrastructure supports the development, deployment, and utilization of a wide range of biosensors.
     
  • Moreover, there is a strong emphasis on technological advancement and healthcare innovation in the UK, supported by both government and private sectors. This includes substantial investments in research and development, public health initiatives, and policies aimed at improving patient outcomes through advanced biosensor technologies.
     

Asia Pacific biosensors industry is anticipated to witness lucrative progression between 2024 and 2032.
 

  • The region is home to a substantial portion of the global population, including countries such as China, India, Japan, and South Korea, which drive higher demand for advanced biosensors across various applications.
     
  • The Asia-Pacific region is also experiencing a rapidly aging population due to factors such as declining birth rates and increased life expectancy, creating a larger pool of individuals in need of advanced health monitoring solutions.
     

The biosensors market in Mexico is expected to experience significant and promising expansion from 2024 to 2032.
 

  • The country has seen a notable increase in the demand for biosensors in recent decades. Factors such as urbanization, rising rates of chronic diseases, and technological advancements have contributed to the growing adoption of biosensors.
     
  • Additionally, Mexico’s growing economy is driving up healthcare expenditures, allowing for greater investment in healthcare services and technologies, including biosensors. Both government and private healthcare providers are allocating more resources to advanced monitoring solutions, driving the demand for biosensors.
     

Biosensors Market Share

The global market is highly competitive and rapidly evolving, driven by advancements in sensor technologies, the increasing demand for real-time health monitoring, and a shift towards personalized medicine. Major players such as Abbott Laboratories and Roche dominate the landscape, while emerging companies are pushing the boundaries of innovation through strategic partnerships and new product developments. As the market expands, competition is intensifying, especially in regions like North America and Asia Pacific, where technological adoption and healthcare expenditures are growing significantly.
 

Biosensors Market Companies

Some of the eminent market participants operating in the biosensors industry include:

  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings
  • Bio-Rad Laboratories
  • Biosensors International Group
  • Danaher Corporation
  • Dexcom
  • F. Hoffmann-La Roche
  • LifeScan
  • Masimo
  • Nova Biomedical
  • Pinnacle Technology
  • QTL Biosystems
  • Siemens Healthineers
  • TE Connectivity Corporation
  • Thermo Fisher Scientific
     

Biosensors Industry News:

  • In March 2024, DexCom, Inc. announced that the FDA approval of Stelo, the first glucose biosensor available without a prescription. This approval makes CGM technology more accessible and could improve the quality of life for many people. It is expected to strengthen DexCom's position in the diabetic care and biosensors business.
     
  • In June 2022, Abbott announced the launch of a bio-wearable device using FreeStyle Libre technology to continuously monitor glucose and ketone levels with a single sensor. This product launch benefited the company by enhancing its product offerings and providing a competitive edge in the market.
     

The biosensors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report


Market, By Type

  • Wearable biosensors
  • Non-wearable biosensors

Market, By Technology

  • Electrochemical
  • Optical
  • Thermal
  • Piezoelectric
  • Other technologies

Market, By Application

  • Blood glucose testing
  • Cholesterol testing
  • Blood gas analysis
  • Pregnancy testing
  • Drug discovery
  • Infectious disease testing
  • Other applications

Market, By End Use 

  • Point of care testing
  • Home healthcare diagnostics
  • Research laboratories
  • Other end users

The above information is provided for the following regions and countries:

  • North Americ 
    • U.S.
    • Canada 
  • Europe 
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
    • Switzerland
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America 
    • Brazil
    • Mexico
  • Middle East and Africa 
    • South Africa
    • Saudi Arabia

 

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global biosensors industry was valued at approximately USD 30.1 billion in 2023 and is estimated to grow at a 7.7% CAGR from 2024 to 2032, driven by the rising global prevalence of diabetes.

The non-wearable biosensors segment held a substantial 64.2% market share in 2023 due to their ease of use, high accuracy, and rapid diagnostic capabilities.

The point-of-care testing (POC) segment is projected to reach USD 29.8 billion by 2032, as biosensors in POC testing provide quick results, crucial for acute conditions and emergencies.

Key players in the industry include Abbott Laboratories, Ascensia Diabetes Care Holdings, Bio-Rad Laboratories, Biosensors International Group, Danaher Corporation, Dexcom, F. Hoffmann-La Roche, LifeScan, Masimo, and Nova Biomedical.

Biosensors Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 240
  • Countries covered: 18
  • Pages: 215
 Download Free Sample